SCHEDULE: Perceptive Advisors Discloses 5.9% Stake in CytomX
Beneficial Ownership Report
Perceptive Advisors and related entities have disclosed a 5.9% beneficial ownership stake in CytomX Therapeutics, Inc., holding 9,680,185 shares.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The Reporting Persons collectively beneficially own 9,680,185 shares of Common Stock of CytomX Therapeutics, Inc.
- This ownership represents 5.9% of the Issuer's outstanding Common Stock.
- The ownership percentage is based on 164,912,906 outstanding shares as of July 31, 2025, as reported in CytomX's Quarterly Report on Form 10-Q filed on August 7, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the 9,680,185 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund and is deemed to beneficially own the securities.
- Joseph Edelman, as the managing member of Perceptive Advisors, is also deemed to beneficially own the securities.
- All Reporting Persons share voting and dispositive power over the 9,680,185 shares.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as the filing indicates a significant investment by a reputable institutional investor, which can be interpreted as a positive signal for the company's prospects, although the filing itself is purely factual.
Positives
- A significant institutional investor, Perceptive Advisors, has disclosed a substantial 5.9% stake, potentially signaling confidence in CytomX Therapeutics, Inc.
Negatives
- NA
Risks
- The filing itself does not detail specific risks related to CytomX Therapeutics, Inc.'s operations or financial health, as it is a beneficial ownership report.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding CytomX Therapeutics, Inc.'s future outlook.
Industry Context
The disclosure of a significant stake by a specialized life sciences investment firm like Perceptive Advisors in a biotechnology company like CytomX Therapeutics, Inc. can be viewed by the market as a vote of confidence, potentially indicating perceived value or future growth potential within the biotech sector.
Comparison to Industry Standards
- This filing is a standard disclosure for institutional investors acquiring more than 5% of a company's shares, aligning with SEC regulations for transparency in beneficial ownership.
- Perceptive Advisors is a prominent investment firm specializing in the life sciences sector, and their investment in CytomX Therapeutics, Inc. is consistent with their strategy of investing in biotechnology and pharmaceutical companies.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially influence stock price positively.
- Company Management: Awareness of a large, active investor like Perceptive Advisors may influence strategic decisions and corporate governance considerations.
Key Dates
| Date | Description |
|---|---|
| 07/31/2025 | Date as of which 164,912,906 shares of Common Stock were outstanding, used as the basis for ownership percentage calculation. |
| 08/07/2025 | Date CytomX Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting outstanding shares. |
| 08/14/2025 | Date of event which required the filing of this statement. |
| 08/21/2025 | Date the Schedule 13G was signed by the Reporting Persons. |
Keywords
CytomX Therapeutics, Perceptive Advisors, Joseph Edelman, Beneficial Ownership, Schedule 13G, Biotechnology, Investment, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.